MARKSANSPharmaceuticals
Marksans Pharma Ltd — Cash Flow Statement
₹156.89
-1.28%
Marksans Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 33.74 Cr | 21.57 Cr | 183.78 Cr | 52.93 Cr | — |
| Repayment Of Debt | -6.01 Cr | -12.50 Cr | — | — | -0.10 Cr |
| Capital Expenditure | -172.92 Cr | -208.84 Cr | -53.63 Cr | -46.33 Cr | — |
| End Cash Position | 495.79 Cr | 403.28 Cr | 382.44 Cr | 206.41 Cr | — |
| Beginning Cash Position | 403.28 Cr | 382.44 Cr | 206.41 Cr | 112.03 Cr | — |
| Changes In Cash | 92.51 Cr | 20.84 Cr | 176.03 Cr | 94.38 Cr | — |
| Financing Cash Flow | -65.15 Cr | -68.73 Cr | 197.83 Cr | 79.51 Cr | — |
| Interest Paid Cff | -2.38 Cr | -5.17 Cr | -6.07 Cr | -8.10 Cr | — |
| Cash Dividends Paid | -27.19 Cr | -22.66 Cr | -10.17 Cr | -10.58 Cr | — |
| Net Issuance Payments Of Debt | -6.01 Cr | -12.50 Cr | 5.30 Cr | 22.55 Cr | — |
| Net Short Term Debt Issuance | -6.01 Cr | -12.50 Cr | 5.30 Cr | 22.55 Cr | — |
| Short Term Debt Payments | -6.01 Cr | -12.50 Cr | — | — | -0.10 Cr |
| Investing Cash Flow | -49.01 Cr | -140.84 Cr | -259.21 Cr | -84.39 Cr | — |
| Interest Received Cfi | 33.80 Cr | 30.87 Cr | 10.42 Cr | 4.76 Cr | — |
| Net Investment Purchase And Sale | 88.86 Cr | 36.28 Cr | -189.77 Cr | -42.85 Cr | — |
| Sale Of Investment | 88.86 Cr | 73.28 Cr | 0.00 | — | — |
| Purchase Of Investment | 0.00 | -37.00 Cr | -189.77 Cr | -42.85 Cr | — |
| Net PPE Purchase And Sale | -171.67 Cr | -207.98 Cr | -53.25 Cr | -46.30 Cr | — |
| Sale Of PPE | 1.25 Cr | 0.85 Cr | 0.38 Cr | 0.03 Cr | — |
| Purchase Of PPE | -172.92 Cr | -208.84 Cr | -53.63 Cr | -46.33 Cr | — |
| Operating Cash Flow | 206.66 Cr | 230.41 Cr | 237.41 Cr | 99.26 Cr | — |
| Taxes Refund Paid | -125.90 Cr | -122.35 Cr | -63.01 Cr | -72.86 Cr | — |
| Change In Working Capital | -240.77 Cr | -126.19 Cr | -111.47 Cr | -110.70 Cr | — |
| Change In Other Current Liabilities | 49.91 Cr | 52.69 Cr | -16.78 Cr | -9.99 Cr | — |
| Change In Other Current Assets | -17.42 Cr | -29.04 Cr | -22.32 Cr | -7.41 Cr | — |
| Change In Inventory | -195.47 Cr | -112.67 Cr | -44.85 Cr | -17.85 Cr | — |
| Change In Receivables | -77.79 Cr | -37.17 Cr | -27.52 Cr | -103.93 Cr | — |
| Other Non Cash Items | -20.81 Cr | -22.58 Cr | -2.84 Cr | 2.47 Cr | — |
| Provisionand Write Offof Assets | 8.33 Cr | 5.16 Cr | 14.36 Cr | 2.63 Cr | — |
| Depreciation And Amortization | 83.39 Cr | 74.27 Cr | 51.85 Cr | 44.78 Cr | — |
| Amortization Cash Flow | 11.22 Cr | 12.30 Cr | 10.48 Cr | 4.09 Cr | — |
| Depreciation | 72.17 Cr | 61.97 Cr | 41.37 Cr | 40.69 Cr | — |
| Gain Loss On Investment Securities | 3.31 Cr | -4.36 Cr | 10.80 Cr | -5.62 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -4.88 Cr | 3.04 Cr | -0.20 Cr | -8.95 Cr | — |
| Gain Loss On Sale Of PPE | 0.03 Cr | -0.09 Cr | 0.26 Cr | 0.00 | — |
| Net Income From Continuing Operations | 503.97 Cr | 423.53 Cr | 337.65 Cr | 247.51 Cr | — |
| Repurchase Of Capital Stock | — | 0.00 | -45.17 Cr | 0.00 | 0.00 |
| Issuance Of Capital Stock | — | 0.00 | 274.71 Cr | 91.16 Cr | 0.00 |
| Effect Of Exchange Rate Changes | — | 0.00 | 20000.00 | 0.00 | — |
| Net Preferred Stock Issuance | — | 0.00 | -5.00 Cr | 0.00 | 0.00 |
| Preferred Stock Payments | — | 0.00 | -5.00 Cr | 0.00 | 0.00 |
| Net Common Stock Issuance | — | 0.00 | 234.54 Cr | 91.16 Cr | 0.00 |
| Common Stock Payments | — | 0.00 | -40.17 Cr | 0.00 | — |
| Common Stock Issuance | — | 0.00 | 274.71 Cr | 91.16 Cr | 0.00 |
| Net Business Purchase And Sale | — | 0.00 | -26.61 Cr | 0.00 | — |
| Purchase Of Business | — | 0.00 | -26.61 Cr | 0.00 | — |
| Issuance Of Debt | — | — | 5.30 Cr | 22.55 Cr | — |
| Short Term Debt Issuance | — | — | 5.30 Cr | 22.55 Cr | — |
| Change In Payable | — | — | 22.42 Cr | 28.48 Cr | 41.78 Cr |
| Dividends Received Cfi | — | — | — | — | 28.35 Cr |
| Pension And Employee Benefit Expense | — | — | — | — | -0.26 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Marksans Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.